Abhishek Jaiswal
Clinical Cardiac Electrophysiology · Shreveport, LANPI 1780093831
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (42.6%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Boston Scientific at 45.6% of the total. Reporting peaked in 2021 at $11,115 and has fallen 51.0% since, to $5,447 in 2025.
Across 262 payments — averaging $123.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$15K
- Abbott$9K
- Medtronic$6K
- Biosense Webster, Inc.$1K
- Biotronik Inc.$177
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$174
- plus $741 from 13 others
What the payments were for
- Grants$13,75043%
- Travel & lodging$9,55530%
- Food & beverage$8,45826%
- Education$5152%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 54 | $14,723 |
| Abbott | 63 | $8,995 |
| Medtronic | 65 | $6,310 |
| Biosense Webster, Inc. | 33 | $1,158 |
| Biotronik Inc. | 3 | $177 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $174 |
| Boehringer Ingelheim | 7 | $156 |
| Bayer | 1 | $125 |
| Johnson & Johnson | 8 | $111 |
| AstraZeneca | 6 | $81 |
| Cardiva Medical, Inc. | 2 | $43 |
| Baxter Healthcare | 1 | $39 |
| Cvrx, Inc. | 1 | $36 |
| Novartis | 2 | $32 |
| Pfizer | 2 | $31 |
| Philips North America LLC | 2 | $30 |
| Kestra Medical Technology Services, Inc. | 1 | $22 |
| Atricure, Inc. | 1 | $18 |
| Angiodynamics, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL BRADY$5,148
- EMBLEM S ICD ELECTRODE DELIVERY SYSTEM$5,000
- EnSite Precision Cardiac Mapping System$1,881
- ENSITE PRECISION$1,374
- INGEVITY$1,206
- Carto 3$788
- EVERA MRI XT DR SURESCAN$635
- SelectSecure$516
- Micra$494
- WATCHMAN Access System$448
- COBALT DR MRI SURESCAN$289
- Ensite Cardiac Mapping System$197
- HeartMate 3 Left Ventricular Dev$172
- BioMonitor$145
- OCTARAY MAPPING CATHETER$143
- Adempas$125
- AZURE XT DR MRI SURESCAN$122
- Xience Sierra Coronary Stent System$122
- EMBLEM$121
- AFFERA MAPPING SYSTEM$101
How this compares
$32,278 in reported general payments places this provider in the 70th percentile of 43 clinical cardiac electrophysiology providers in Louisiana.
See all clinical cardiac electrophysiology providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 279 | $197,150 |
| EntrestoSacubitril/Valsartan | 46 | $34,930 |
| XareltoRivaroxaban | 51 | $25,489 |
| JardianceEmpagliflozin | 23 | $14,595 |
| Metoprolol Succinate | 243 | $1,742 |
| Amiodarone Hcl | 91 | $1,532 |
| SotalolSotalol Hcl | 109 | $1,169 |
| ClopidogrelClopidogrel Bisulfate | 102 | $740 |
| Losartan Potassium | 120 | $650 |
| Flecainide Acetate | 33 | $612 |
| Amlodipine Besylate | 156 | $535 |
| Metoprolol Tartrate | 133 | $519 |
| Potassium Chloride | 35 | $469 |
| Carvedilol | 65 | $321 |
| Furosemide | 105 | $261 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $31 | $197,150279 claims |
| NovartisEntresto | $32 | $34,93046 claims |
| Johnson & JohnsonXarelto | $111 | $25,48951 claims |
| Boehringer IngelheimJardiance | $156 | $14,59523 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 43 clinical cardiac electrophysiology providers in Louisiana.
Other clinical cardiac electrophysiology in Shreveport
- Bader AlotaibiShreveport$31K
- Ashritha PenagaluriShreveport$26K
- Vijaywant BrarShreveport$25K
- Sherman WigginsShreveport$12K
- Srikar VeerareddyShreveport$7K
- Sai KonduruShreveport$2K
- Nassir MarroucheNew Orleans$498K
- Sammy KhatibNew Orleans$115K
- Paul LelorierNew Orleans$101K
- Adil YousufNew Orleans$101K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.